Skip to main content
U.S. flag

An official website of the United States government

Malarone treatment failure and

Published by National Institutes of Health | U.S. Department of Health & Human Services | Catalog Last Checked: September 07, 2025 at 01:42 PM | Dataset Last Updated: September 06, 2025
We report the first in vitro and genetic confirmation of Malarone® (GlaxoSmithKline; atovaquone and proguanil hydrochloride) resistance in Plasmodium falciparum acquired in Africa. On presenting with malaria two weeks after returning from a 4-week visit to Lagos, Nigeria without prophylaxis, a male patient was given a standard 3-day treatment course of Malarone®. Twenty-eight days later the parasitaemia recrudesced. Parasites were cultured from the blood and the isolate (NGATV01) was shown to be resistant to atovaquone and the antifolate pyrimethamine. The cytochrome b gene of isolate NGATV01 showed a single mutation, Tyr268Asn which has not been seen previously.

Resources

1 resource available

  • Official Government Data Source

    TEXT/HTML

Find Related Datasets

data.gov

An official website of the GSA's Technology Transformation Services

Looking for U.S. government information and services?
Visit USA.gov